share_log

SVB Leerink Maintains Market Perform on Atea Pharmaceuticals, Lowers Price Target to $6

SVB Leerink Maintains Market Perform on Atea Pharmaceuticals, Lowers Price Target to $6

SVB Leerink维持Atea Pharmicals的市场表现,将目标价下调至6美元
Benzinga Real-time News ·  2023/01/27 05:48

SVB Leerink analyst Roanna Ruiz maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Market Perform and lowers the price target from $8 to $6.

SVB Leerink分析师Roanna Ruiz维持ATEA制药(纳斯达克:AVIR)的市场表现,并将目标价从8美元下调至6美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发